JPRN-jRCT1080223624已完成1 期
A randomized, placebo-controlled, double-blind study to assess the safety, tolerability and pharmacokinetics of single and multiple doses of DS-5565 in healthy Chinese subjects
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 54
研究概览
简要总结
DS-5565 was safe and well-tolerated at single doses of 5 mg to 15 mg and at multiple doses of up to 15 mg in healthy Chinese subjects.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 45age old（—）
- 性别
- All
入选标准
- •1)Healthy Chinese
- •2)Aged 18 years to 45 years (inclusive), at the time of informed consent
- •3)Body weight of female >= 45 kg, male >= 50 kg, and a BMI in the range of 19.0 kg/m2 to 26.0 kg/m2 (inclusive) at screening
排除标准
- •1)Hypersensitivity or idiosyncratic reactions to a drug (such as penicillin allergy)
- •2)Presence or history of any drug abuse or of alcohol abuse etc.
研究者
相似试验
已完成
1 期
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ION547Healthy VolunteersNCT04934891Ionis Pharmaceuticals, Inc.48
已完成
1 期
A single-dose ascending study and a multiple-dose study in healthy male subjects and a multiple-dose study in subjects who have no more than 3 spontaneous bowel movements per week to investigate the tolerability, safety, pharmacokinetics, and pharmacodynamics of DSP-6952, and a single-dose study in healthy male subjects to examine the effect of food.Part A and BHealthy adult male subjects Part CAdult subjects with spontaneous bowel movements 3 times or less a weekJPRN-jRCT2080223728Sumitomo Dainippon Pharma Co., Ltd.88
已完成
1 期
Safety and Tolerability of Single and Multiple Doses of ISIS 353512 in Healthy VolunteersInflammatory DiseasesNCT00734240Ionis Pharmaceuticals, Inc.103
已完成
1 期
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple DosingTuberculosis, PulmonaryNCT03776500Innovative Medicines for Tuberculosis32
已完成
1 期
VRS-317 in Adult Subjects With Growth Hormone DeficiencyGrowth Hormone DeficiencyNCT01359488Versartis Inc.50